The present invention relates to a peptide comprising at least 12 amino acid residues from the N-terminal end of gas-tric inhibitory polypeptide, or an analogue thereof, which are useful to prophylactically prevent, improve, or reverse the diminished cognitive function associated with these types of disorders, by increasing (or sustaining) the LTP of synaptic transmission. Moreover, sustaining LTP may find utility in the prophylaxis of neurological disease by delaying the onset of impaired cognitive processes, and could serve as a treatment, not only for the diminished cognitive function caused by neurodegeneration, but also for the dysfunctional cognitive processes associated with trauma or age. Additionally, the peptides and analogues of the present invention find are useful to improve the altered cognitive function associated with hyperexcitability-type disorders, by reducing the elevated level of LTP of synaptic transmission.
USE OF GIP FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH DYSFUNCTIONAL SYNAPTIC TRANSMISSION